Relationships of insulin-like growth factor-1, its binding proteins, and cardiometabolic risk in hypertensive perimenopausal women

Metabolism: Clinical and Experimental

Volumn 69, Issue , 2017, Pages 96-106

  Olszanecka, Agnieszka ^a   Dragan, Aneta ^a   Kawecka Jaszcz, Kalina ^a   Fedak, Danuta ^a   Czarnecka, Danuta ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Hypertension; IGFBP 2; Left ventricular geometry; Metabolic syndrome

Indexed keywords

HEMOGLOBIN; LEPTIN; SEX HORMONE; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL; SOMATOMEDIN BINDING PROTEIN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE CUFF; BLOOD PRESSURE MONITORING; BODY COMPOSITION; BODY MASS; CARDIOMETABOLIC RISK; CAROTID ARTERY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; FEMORAL ARTERY; HEART LEFT VENTRICLE MASS; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOCHEMISTRY; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; OBSTETRIC ULTRASOUND TRANSDUCER; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIAGNOSTIC IMAGING; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; MENOPAUSE; METABOLIC DISEASES; METABOLISM; MIDDLE AGED; RISK ASSESSMENT;

ADULT; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; MENOPAUSE; METABOLIC DISEASES; METABOLIC SYNDROME X; MIDDLE AGED; PULSE WAVE ANALYSIS; RISK ASSESSMENT;

EID: 85009865321     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2017.01.005     Document Type: Article

References (44)

1. [1] Jones, J.I., Clemmons, D.R., Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16 (1995), 3–34, 10.1210/edrv-16-1-3.
2. [2] Izhar, U., Hasadi, D., Richardson, D.M., Cohen, P., Lerman, A., Insulin and insulin-like growth factor-I cause vasorelaxation in human cells in vitro. Coron Artery Dis 11 (2000), 69–76.
3. [3] Schutte, A.E., Schutte, R., Smith, W., Huisman, H.W., Mels, C.M.C., Malan, L., et al. Compromised bioavailable IGF-1 of black men relates favourably to ambulatory blood pressure: the SABPA study. Atherosclerosis 233 (2014), 139–144, 10.1016/j.atherosclerosis.2013.12.025.
4. [4] Zhang, L., Curhan, G.C., Forman, J.P., Plasma insulin-like growth factor-1 level and risk of incident hypertension in nondiabetic women. J Hypertens 29 (2011), 229–235, 10.1097/HJH.0b013e32834103bf.
5. [5] Clauson, P.G., Brismar, K., Hall, K., Linnarsson, R., Grill, V., Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand J Clin Lab Invest 58 (1998), 353–360.
6. [6] Lawlor, D.A., Ebrahim, S., Smith, G.D., Cherry, L., Watt, P., Sattar, N., The association of insulin-like-growth factor 1 (IGF-1) with incident coronary heart disease in women: findings from the prospective British Women's Heart and Health Study. Atherosclerosis 201 (2008), 198–204, 10.1016/j.atherosclerosis.2007.12.061.
7. [7] Nindl, B.C., Santtila, M., Vaara, J., Hakkinen, K., Kyrolainen, H., Circulating IGF-I is associated with fitness and health outcomes in a population of 846 young healthy men. Growth Horm IGF Res 21 (2011), 124–128, 10.1016/j.ghir.2011.03.001.
8. [8] Ezzat, V.A., Duncan, E.R., Wheatcroft, S.B., Kearney, M.T., The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes Obes Metab 10 (2008), 198–211, 10.1111/j.1463-1326.2007.00709.x.
9. [9] Maile, L.A., Holly, J.M.P., Insulin-like growth factor binding protein (IGFBP) proteolysis: occurrence, identification, role and regulation. Growth Horm IGF Res 9 (1999), 85–95, 10.1054/ghir.1999.0096.
10. [10] Kim, H.-S., Nagalla, S.R., Oh, Y., Wilson, E., Roberts, C.T.J., Rosenfeld, R.G., Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. PNAS 94 (1997), 12981–12986, 10.1073/pnas.94.24.12981.
11. [11] Boisclair, Y.R., Rhoads, R.P., Ueki, I., Wang, J., Ooi, G.T., The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 170 (2001), 63–70, 10.1677/joe.0.1700063.
12. [12] Lee, P.D., Giudice, L.C., Conover, C.A., Powell, D.R., Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 216 (1997), 319–357, 10.3181/00379727-216-44182.
13. [13] Cruickshank, J.K., Heald, A.H., Anderson, S., Cade, J.E., Sampayo, J., Riste, L.K., et al. Epidemiology of the insulin-like growth factor system in three ethnic groups. Am J Epidemiol 154 (2001), 504–513, 10.1093/aje/154.6.504.
14. [14] Boney, C.M., Moats-Staats, B.M., Stiles, A.D., D'Ercole, A.J., Expression of insulin-like growth factor-I (IGF-I) and IGF-binding proteins during adipogenesis. Endocrinology 135 (1994), 1863–1868, 10.1210/endo.135.5.7525256.
15. [15] Heald, A.H., Kaushal, K., Siddals, K.W., Rudenski, A.S., Anderson, S.G., Gibson, J.M., Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp Clin Endocrinol Diabetes 114 (2006), 371–376, 10.1055/s-2006-924320.
16. [16] Wheatcroft, S.B., Kearney, M.T., Shah, A.M., Ezzat, V.A., Miell, J.R., Modo, M., et al. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 56 (2007), 285–294, 10.2337/db06-0436.
17. [17] Carter, S., Li, Z., Lemieux, I., Alméras, N., Tremblay, A., Bergeron, J., et al. Circulating IGFBP-2 levels are incrementally linked to correlates of the metabolic syndrome and independently associated with VLDL triglycerides. Atherosclerosis 237 (2014), 645–651, 10.1016/j.atherosclerosis.2014.09.022.
18. [18] Kische, H., Gross, S., Wallaschofski, H., Völzke, H., Dörr, M., Nauck, M., et al. Clinical correlates of sex hormones in women: the study of health in Pomerania. Metabolism 65 (2016), 1286–1296, 10.1016/j.metabol.2016.05.011.
19. [19] Olszanecka, A., Pośnik-Urbańska, A., Kawecka-Jaszcz, K., Czarnecka, D., Fedak, D., Adipocytokines and blood pressure, lipids and glucose metabolism in hypertensive perimenopausal women. Kardiol Pol 68 (2010), 753–760.
20. [20] Olszanecka, A., Kawecka-Jaszcz, K., Czarnecka, D., Association of free testosterone and sex hormone binding globulin with metabolic syndrome and subclinical atherosclerosis but not blood pressure in hypertensive perimenopausal women. Arch Med Sci 12 (2016), 521–528, 10.5114/aoms.2016.59925.
21. [21] Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34 (2013), 2159–2219, 10.1093/eurheartj/eht151.
22. [22] Lang, R.M., Badano, L.P., Mor-Avi, V., Afilalo, J., Armstrong, A., Ernande, L., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16 (2015), 233–271, 10.1093/ehjci/jev014.
23. [23] Vermeulen, A., Verdonck, L., Kaufman, J.M., A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84 (1999), 3666–3672, 10.1210/jcem.84.10.6079.
24. [24] Bonora, E., Targher, G., Alberiche, M., Bonadonna, R.C., Saggiani, F., Zenere, M.B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23 (2000), 57–63, 10.2337/diacare.23.1.57.
25. [25] Alberti, K.G.M.M., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International. Circulation 120 (2009), 1640–1645, 10.1161/circulationaha.109.192644.
26. [26] Khoshravesh, M., Gholami Sefidkouhi, M.A., Valipour, M., Estimation of reference evapotranspiration using multivariate fractional polynomial, Bayesian regression, and robust regression models in three arid environments. Appl Water Sci, 2015, 10.1007/s13201-015-0368-x.
27. [27] Heald, A., Kaushal, K., Anderson, S., Redpath, M., Durrington, P.N., Selby, P.L., et al. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk. Gynecol Endocrinol 20 (2005), 176–182, 10.1080/09513590400027406.
28. [28] Martin, R.M., Gunnell, D., Whitley, E., Nicolaides, A., Griffin, M., Georgiou, N., et al. Associations of insulin-like growth factor (IGF)-I, IGFII, IGF binding protein (IGFBP)-2 and IGFBP-3 with ultrasound measures of atherosclerosis and plaque stability in an older adult population. J Clin Endocrinol Metab 93 (2008), 1331–1338, 10.1210/jc.2007-2295.
29. [29] Colangelo, L.A., Liu, K., Gapstur, S.M., Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and cardiovascular disease risk factors in young black men and white men: the CARDIA male hormone study. Am J Epidemiol 160 (2004), 750–757, 10.1093/aje/kwh289.
30. [30] Russo, V.C., Azar, W.J., Yau, S.W., Sabin, M.A., Werther, G.A., IGFBP-2: the dark horse in metabolism and cancer. Cytokine Growth Factor Rev 26 (2015), 329–346, 10.1016/j.cytogfr.2014.12.001.
31. [31] Hedbacker, K., Birsoy, K., Wysocki, R.W., Asilmaz, E., Ahima, R.S., Farooqi, I.S., et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab 11 (2010), 11–22, 10.1016/j.cmet.2009.11.007.
32. [32] Wheatcroft, S.B., Kearney, M.T., IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab 20 (2009), 153–162, 10.1016/j.tem.2009.01.002.
33. [33] Rajpathak, S.N., He, M., Sun, Q., Kaplan, R.C., Muzumdar, R., Rohan, T.E., et al. Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes 61 (2012), 2248–2254, 10.2337/db11-1488.
34. [34] Ko, J.M., Park, H.K., Yang, S., Hwang, I.T., Influence of catch-up growth on IGFBP-2 levels and association between IGFBP-2 and cardiovascular risk factors in Korean children born SGA. Endocr J 59 (2012), 725–733, 10.1507/endocrj.EJ12-0080.
35. [35] Sharples, A.P., Al-Shanti, N., Hughes, D.C., Lewis, M.P., Stewart, C.E., The role of insulin-like-growth factor binding protein 2 (IGFBP2) and phosphatase and tensin homologue (PTEN) in the regulation of myoblast differentiation and hypertrophy. Growth Horm IGF Res 23 (2013), 53–61, 10.1016/j.ghir.2013.03.004.
36. [36] Rehfeldt, C., Renne, U., Sawitzky, M., Binder, G., Hoeflich, A., Increased fat mass, decreased myofiber size, and a shift to glycolytic muscle metabolism in adolescent male transgenic mice overexpressing IGFBP-2. Am J Physiol Endocrinol Metab 299 (2010), E287–E298, 10.1152/ajpendo.00492.2009.
37. [37] Shai, S.Y., Harpf, A.E., Babbitt, C.J., Jordan, M.C., Fishbein, M.C., Chen, J., et al. Cardiac myocyte-specific excision of the beta1 integrin gene results in myocardial fibrosis and cardiac failure. Circ Res 90 (2002), 458–464, 10.1161/hh0402.105790.
38. [38] Berry, M., Galinier, M., Delmas, C., Fournier, P., Desmoulin, F., Turkieh, A., et al. Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure. IJC Metab Endocr 6 (2015), 5–12, 10.1016/j.ijcme.2014.11.003.
39. [39] Carter, S., Capoulade, R., Arsenault, M., Bédard, É., Dumesnil, G., Mathieu, P., et al. Relationship between insulin-like growth factor binding protein-2 and left ventricular stroke volume in patients with aortic stenosis. Can J Cardiol, 31, 2015, 1447.
40. [40] Zachariah, J.P., Xanthakis, V., Larson, M.G., Vita, J.A., Sullivan, L.M., Smith, H.M., et al. Circulating vascular growth factors and central hemodynamic load in the community. Hypertension 59 (2012), 773–779, 10.1161/HYPERTENSIONAHA.111.179242.
41. [41] Hoeflich, A., Russo, V.C., Physiology and pathophysiology of IGFBP-1 and IGFBP-2—consensus and dissent on metabolic control and malignant potential. Best Pract Res Clin Endocrinol Metab 29 (2015), 685–700, 10.1016/j.beem.2015.07.002.
42. [42] Amin, S., Riggs, B.L., Atkinson, E.J., Oberg, A.L., Melton, L.J., Khosla, S., A potentially deleterious role of IGFBP-2 on bone density in aging men and women. J Bone Miner Res 19 (2004), 1075–1083, 10.1359/JBMR.040301.
43. [43] Lukanova, A., Lundin, E., Zeleniuch-Jacquotte, A., Muti, P., Mure, A., Rinaldi, S., et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 150 (2004), 161–171, 10.1530/eje.0.1500161.
44. [44] Denroche, H.C., Huynh, F.K., Kieffer, T.J., The role of leptin in glucose homeostasis. J Diabetes Investig 3 (2012), 115–129, 10.1111/j.2040-1124.2012.00203.x.